Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Participants' uptake of clinical trial results: a randomised experiment.
Mancini J, Genre D, Dalenc F, Ferrero JM, Kerbrat P, Martin AL, Roché H, Maylevin F, Tarpin C, Viens P, Genève J, Julian-Reynier C. Mancini J, et al. Among authors: kerbrat p. Br J Cancer. 2010 Mar 30;102(7):1081-4. doi: 10.1038/sj.bjc.6605592. Epub 2010 Mar 2. Br J Cancer. 2010. PMID: 20197767 Free PMC article. Clinical Trial.
5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study.
Ploquin A, Pistilli B, Tresch E, Frenel JS, Lerebours F, Lesur A, Loustalot C, Bachelot T, Provansal M, Ferrero JM, Coussy F, Debled M, Kerbrat P, Vinceneux A, Allouache D, Morvan F, Dalenc F, Guiu S, Rouzier R, Vanlemmens L. Ploquin A, et al. Among authors: kerbrat p. Eur J Cancer. 2018 May;95:30-37. doi: 10.1016/j.ejca.2018.02.030. Epub 2018 Apr 3. Eur J Cancer. 2018. PMID: 29625257
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.
Pierga JY, Bidard FC, Autret A, Petit T, Andre F, Dalenc F, Levy C, Ferrero JM, Romieu G, Bonneterre J, Lerebours F, Bachelot T, Kerbrat P, Campone M, Eymard JC, Mouret-Reynier MA, Gligorov J, Hardy-Bessard AC, Lortholary A, Soulie P, Boher JM, Proudhon C, Charafe-Jaufret E, Lemonnier J, Bertucci F, Viens P. Pierga JY, et al. Among authors: kerbrat p. Ann Oncol. 2017 Jan 1;28(1):103-109. doi: 10.1093/annonc/mdw535. Ann Oncol. 2017. PMID: 28177480 Free article. Clinical Trial.
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
Kerbrat P, Roché H, Bonneterre J, Veyret C, Lortholary A, Monnier A, Fumoleau P, Fargeot P, Namer M, Chollet P, Goudier MJ, Audhuy B, Simon H, Montcuquet P, Eymard JC, Walter S, Clavère P, Guastalla JP; French adjuvant Study Group. Kerbrat P, et al. Br J Cancer. 2007 Jun 4;96(11):1633-8. doi: 10.1038/sj.bjc.6603773. Epub 2007 May 15. Br J Cancer. 2007. PMID: 17505516 Free PMC article. Clinical Trial.
A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
Dieras V, Chevallier B, Kerbrat P, Krakowski I, Roche H, Misset JL, Lentz MA, Azli N, Murawsky M, Riva A, Pouillart P, Fumoleau P. Dieras V, et al. Among authors: kerbrat p. Br J Cancer. 1996 Aug;74(4):650-6. doi: 10.1038/bjc.1996.416. Br J Cancer. 1996. PMID: 8761385 Free PMC article. Clinical Trial.
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
Delaloge S, Pérol D, Courtinard C, Brain E, Asselain B, Bachelot T, Debled M, Dieras V, Campone M, Levy C, Jacot W, Lorgis V, Veyret C, Dalenc F, Ferrero JM, Uwer L, Kerbrat P, Goncalves A, Mouret-Reynier MA, Petit T, Jouannaud C, Vanlemmens L, Chenuc G, Guesmia T, Robain M, Cailliot C. Delaloge S, et al. Among authors: kerbrat p. Ann Oncol. 2016 Sep;27(9):1725-32. doi: 10.1093/annonc/mdw260. Epub 2016 Jul 19. Ann Oncol. 2016. PMID: 27436849 Free article.
Individualized Prediction of Menses Recovery After Chemotherapy for Early-stage Breast Cancer: A Nomogram Developed From UNICANCER PACS04 and PACS05 Trials.
Pistilli B, Mazouni C, Zingarello A, Faron M, Saghatchian M, Grynberg M, Spielmann M, Kerbrat P, Roché H, Lorgis V, Bachelot T, Campone M, Levy C, Gonçalves A, Lesur A, Veyret C, Vanlemmens L, Lemonnier J, Delaloge S. Pistilli B, et al. Among authors: kerbrat p. Clin Breast Cancer. 2019 Feb;19(1):63-70. doi: 10.1016/j.clbc.2018.08.005. Epub 2018 Aug 23. Clin Breast Cancer. 2019. PMID: 30241966 Clinical Trial.
Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.
Loriot Y, Pagliaro L, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Laplanche A, Le Teuff G, Culine S, Fizazi K. Loriot Y, et al. Among authors: kerbrat p. Eur J Cancer. 2017 Dec;87:140-146. doi: 10.1016/j.ejca.2017.09.029. Epub 2017 Nov 14. Eur J Cancer. 2017. PMID: 29149760 Clinical Trial.
215 results